Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Therapeutics Deals

TORONTO, MONTREAL,VANCOUVER, British Columbia December 19, 2016 - Versant Ventures today announced that Toronto-based portfolio company Northern Biologics Inc. has executed a transformational deal that expands its pipeline and financial resources, bringing the total commitments to Versant’s Canadian biotech portfolio to over CAD$500 million. The merger of Mosaic Biomedicals SL with Northern creates a global oncology company backed by Versant and Celgene Corp. (NASDAQ:CELG) that will advance a promising first-in-class antibody into clinical trials in 2017.

For the Full Press Release Click Here